EP2091428A2 - Détection de l'insuffisance cardiaque au moyen d'un photopléthysmographe - Google Patents

Détection de l'insuffisance cardiaque au moyen d'un photopléthysmographe

Info

Publication number
EP2091428A2
EP2091428A2 EP07805552A EP07805552A EP2091428A2 EP 2091428 A2 EP2091428 A2 EP 2091428A2 EP 07805552 A EP07805552 A EP 07805552A EP 07805552 A EP07805552 A EP 07805552A EP 2091428 A2 EP2091428 A2 EP 2091428A2
Authority
EP
European Patent Office
Prior art keywords
patient
signal
cheyne
processor
photoplethysmograph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07805552A
Other languages
German (de)
English (en)
Other versions
EP2091428A4 (fr
Inventor
Daniel Reisfeld
Hila Sberro
Simon Kogan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Widemed Ltd
Original Assignee
Widemed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/750,222 external-priority patent/US7803118B2/en
Application filed by Widemed Ltd filed Critical Widemed Ltd
Publication of EP2091428A2 publication Critical patent/EP2091428A2/fr
Publication of EP2091428A4 publication Critical patent/EP2091428A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/024—Detecting, measuring or recording pulse rate or heart rate
    • A61B5/02416—Detecting, measuring or recording pulse rate or heart rate using photoplethysmograph signals, e.g. generated by infrared radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
    • A61B5/0826—Detecting or evaluating apnoea events
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4806—Sleep evaluation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4806—Sleep evaluation
    • A61B5/4809—Sleep detection, i.e. determining whether a subject is asleep or not
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4806—Sleep evaluation
    • A61B5/4812—Detecting sleep stages or cycles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4806—Sleep evaluation
    • A61B5/4815—Sleep quality
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4806—Sleep evaluation
    • A61B5/4818—Sleep apnoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/6802—Sensor mounted on worn items
    • A61B5/681—Wristwatch-type devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/6813—Specially adapted to be attached to a specific body part
    • A61B5/6825—Hand
    • A61B5/6826—Finger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/683—Means for maintaining contact with the body
    • A61B5/6838—Clamps or clips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7203—Signal processing specially adapted for physiological signals or for diagnostic purposes for noise prevention, reduction or removal
    • A61B5/7207—Signal processing specially adapted for physiological signals or for diagnostic purposes for noise prevention, reduction or removal of noise induced by motion artifacts
    • A61B5/721—Signal processing specially adapted for physiological signals or for diagnostic purposes for noise prevention, reduction or removal of noise induced by motion artifacts using a separate sensor to detect motion or using motion information derived from signals other than the physiological signal to be measured

Definitions

  • the present invention relates generally to physiological monitoring and diagnosis, and specifically to sleep recording and analysis. BACKGROUND OF THE INVENTION
  • Human sleep is generally described as a succession of five recurring stages (plus waking, which is sometimes classified as a sixth stage). Sleep stages are typically monitored using a polysomnograph to collect physiological signals from the sleeping subject, including brain waves (EEG), eye movements (EOG) 3 muscle activity (EMG), heartbeat (ECG), blood oxygen levels (SpO2) and respiration.
  • EEG brain waves
  • EMG eye movements
  • EMG heartbeat
  • SpO2 blood oxygen levels
  • respiration respiration.
  • the commonly-recognized stages include:
  • Stage 1 sleep or drowsiness.
  • the eyes are closed during Stage 1 sleep, but if aroused from it, a person may feel as if he or she has not slept.
  • Stage 2 is a period of light sleep, during which the body prepares to enter deep sleep.
  • Stages 3 and 4 are deep sleep stages, with Stage 4 being more intense than Stage 3.
  • Stage 5 REM (rapid eye movement) sleep, is distinguishable from non-REM (NREM) sleep by changes in physiological states, including its characteristic rapid eye movements. Polysomnograms show brain wave patterns in REM to be similar to Stage 1 sleep. In normal sleep, heart rate and respiration speed up and become erratic, while the muscles may twitch. Intense dreaming occurs during REM sleep, but paralysis occurs simultaneously in the major voluntary muscle groups.
  • Sleep apneas commonly occur in conjunction with a variety of cardiorespiratory disorders.
  • the relationship between sleep apnea and heart failure, for example, is surveyed by Bradley et al. in two articles entitled “Sleep Apnea and Heart Failure,” including “Part I: Obstructive Sleep Apnea,” Circulation 107, pages 1671-1678 (2003), and “Part II: Central Sleep Apnea,” Circulation 107, pages 1822-1826 (2003), which are incorporated herein by reference.
  • the authors define "apnea” as a cessation of airflow for more than 10 sec.
  • hypopnea is a reduction in but not complete cessation of airflow to less than 50% of normal, usually in association with a reduction in oxyhemoglobin saturation (commonly referred to as “desaturation”).
  • sleep apneas and hypopneas are generally believed to fall into two categories: obstructive, due to collapse of the pharynx; and central, due to withdrawal of central respiratory drive to the muscles of respiration.
  • CSA Central sleep apnea
  • Cheyne-Stokes respiration which is a form 6f periodic breathing in which central apneas and hypopneas alternate with periods of hyperventilation, with a waxing-waning pattern of tidal volume.
  • CSA is believed to arise as the result of heart failure, though obstructive sleep apnea (OSA) may also occur in heart failure patients.
  • OSA obstructive sleep apnea
  • Both OSA and CSA increase the strain on the cardiovascular system and thus worsen the prognosis of the heart failure patient. In some cases, both types of apneas may occur in the same patient, even at the same time (superposition). Classifying respiratory events as central or obstructive is considered to be a critical point, since treatment may differ according to the type of events, as pointed out by Pepin et al. in "Cheyne-Stokes Respiration with Central Sleep Apnea in Chronic Heart Failure: Proposals for a Diagnostic and Therapeutic Strategy," Sleep Medicine Reviews 10, pages 33-47 (2006), which is incorporated herein by reference. Both CSA and OSA can be manifested in periodic breathing patterns.
  • U.S. Patent Application Publication US 2004/0230105 Al describes a method for analyzing respiratory signals using a Fuzzy Logic Decision Algorithm (FLDA). The method may be used to associate respiratory disorders with obstructive apnea, hypopnea, central apnea, or other conditions.
  • FLDA Fuzzy Logic Decision Algorithm
  • U.S. Patent Application Publication US 2002/0002327 Al and U.S. Patent 6,839,581 describe methods for detecting Cheyne-Stokes respiration, which may be used on patients with heart failure.
  • the methods involve performing spectral analysis of overnight oximetry recordings, from which a classification tree is generated. Another method, based on monitoring oxygen saturation and calculating the slope of desaturation events, is described in U.S. Patent 6,760,608. Yet another method for classifying sleep apneas is described in U.S. Patent 6,856,829. In this case, pulse waves from the body of a patient are detected, and the envelope of the pulse waves is created by connecting every peak of the pulse waves. The normalized amplitude and period of the envelope are used in determining whether the patient has OSA, CSA, or mixed sleep apnea syndrome. The disclosures of the patents and patent applications cited above are incorporated herein by reference.
  • U.S. Patent 5,902,250 whose disclosure is incorporated herein by reference, describes a home-based, wearable, self-contained system that determines sleep-state and respiratory pattern, and assesses cardiorespiratory risk.
  • a respiratory disorder may be diagnosed from the frequency of eyelid movements and/or from ECG signals.
  • Cardiac disorders (such as cardiac arrhythmia or myocardial ischemia) that are known to be linked to certain respiratory disorders also may be inferred upon detection of such respiratory disorders.
  • Photoplethysmograph devices known commonly as pulse oximeters, provide instantaneous in vivo measurement of arterial oxygenation by determining the color of blood between a light source and a photodetector. To determine the blood oxygen saturation, light absorption measurement is carried out at two wavelengths in the red and infrared ranges. The difference between background absorption during diastole and peak absorption during systole at both wavelengths is used to compute the blood oxygen saturation.
  • Photoplethysmograph signals provide information not only on blood oxygenation, but also on other physiological signs.
  • U.S. Patent 5,588,425 describes the use of a pulse oximeter in validating the heart rate and/or R-R intervals of an ECG, and for discriminating between sleep and wakefulness in a monitored subject. It also describes a method for distinguishing between valid pulse waveforms in the oximeter signal.
  • U.S. Patent 7,001,337 describes a method for obtaining physiological parameter information related to respiration rate, heart rate, heart rate variability, blood volume variability and/or the autonomic nervous system using photoplethysmography.
  • Patent 7,190,261 describes an arrhythmia alarm processor, which detects short-duration, intermittent oxygen desaturations of a patient using a pulse oximeter as a sign of irregular heartbeat. An alarm is triggered when the pattern of desaturations matches a reference pattern.
  • the disclosures of the above-mentioned patents are incorporated herein by reference.
  • the photoplethysmograph signals that are output by a standard pulse oximeter can provide a wealth of information regarding the patient's vital signs and physiological condition.
  • photoplethysmograph signals that are captured while the patient sleeps are analyzed in order to diagnose the patient's cardiorespiratory condition.
  • the signals may be used to detect and assess the severity of conditions that are characteristic of heart failure (HF), such as premature ventricular contractions and Cheyne-Stokes breathing.
  • HF heart failure
  • the photoplethysmograph signals may also be used, even without monitoring other physiological parameters, to classify the sleep stages and "sleep quality" of the patient.
  • the power and versatility of the photoplethysmograph-based techniques that are described hereinbelow make it possible to monitor patients' oxygen saturation, heartbeat, respiration, sleep stages and autonomic nervous system during sleep using no more than a single pulse oximeter probe (which typically clips onto the patient's finger). As a result, the patient may be monitored comfortably and conveniently, at home or in a hospital bed, even without on-site assistance in setting up each night's monitoring.
  • the principles of the present invention may be applied to analysis of respiration signals captured using monitors of other types.
  • a method for diagnosis including: receiving a signal associated with blood oxygen saturation of a patient during sleep; filtering the signal so as to eliminate signal components at frequencies equal to and greater than a respiratory frequency of the patient; and processing the filtered signal to detect a pattern corresponding to multiple cycles of periodic breathing.
  • processing the filtered signal includes detecting the signal components that have a period greater than a minimum period of at least 30 sec, wherein the minimum period may be at least 55 sec.
  • processing the filtered signal includes detecting occurrences of a pattern of Cheyne-Stokes breathing, and the method includes determining a prognosis of heart failure (HF) in the patient based on the occurrences of the pattern of Cheyne-Stokes breathing.
  • HF heart failure
  • Determining the prognosis may include predicting a probability of survival of the patient or predicting a level of at least one marker, selected from a group of markers consisting of Brain
  • BNP Basal prohormone Brain Natriuretic Peptide
  • NT proBNP N-terminal prohormone Brain Natriuretic Peptide
  • determining the prognosis may include differentiating compensated from decompensated heart failure, predicting a hospitalization of the patient, or providing an indication of a need for a change in treatment of the patient.
  • receiving the signal includes receiving a photoplethysmograph signal from a sensor coupled to a body of a patient, and the method includes processing the photoplethysmograph signal so as to identify a cardiac arrhythmia of the patient.
  • determining the prognosis includes finding the prognosis responsively both to the occurrences of the pattern of Cheyne-Stokes breathing and to the cardiac arrhythmia.
  • determining the prognosis includes assessing a duration of the occurrences of a pattern of Cheyne-Stokes breathing.
  • the method may include treating the patient so as to reduce the duration of the occurrences of the pattern of Cheyne-Stokes breathing.
  • assessing the duration includes finding a cumulative duration of the occurrences of the pattern of Cheyne-Stokes breathing, and classifying the patient in a high-mortality group if the cumulative duration exceeds a predetermined threshold, typically at least 45 minutes.
  • detecting the occurrences includes identifying a Cheyne-Stokes breathing event when a duration of the multiple cycles is no less than a predetermined minimum duration. Additionally or alternatively, detecting the occurrences includes identifying a Cheyne-Stokes breathing event when a number of the multiple cycles is no less than a predetermined minimum number, such as three.
  • detecting the occurrences includes identifying a Cheyne-Stokes breathing event when a representative level of the blood oxygen saturation during the cycles is less than the blood oxygen saturation before the cycles by at least a predetermined amount.
  • the representative level of the blood oxygen saturation may be one of a median saturation, a mean saturation, and a minimum saturation during the cycles.
  • the Cheyne-Stokes breathing event is identified when the representative level of the blood oxygen saturation is less than the blood oxygen saturation before the cycles by at least 2%.
  • detecting the occurrences includes distinguishing the
  • distinguishing the Cheyne-Stokes breathing events includes determining a slope of the filtered signal, and distinguishing the Cheyne-Stokes breathing events responsively to the slope.
  • determining the slope includes finding a measure of the slope selected from a group of measures consisting of a median slope and a mean slope, and distinguishing the Cheyne-Stokes breathing events based on a maximal value of the measure of the slope in each of the cycles.
  • Distinguishing the Cheyne-Stokes breathing events may include classifying a breathing event as Cheyne-Stokes only when the maximal value of the measure is no greater than 0.7%/sec.
  • the method includes screening the patient for heart failure based on the occurrences of the pattern of Cheyne-Stokes breathing.
  • receiving the signal includes receiving a photoplethysmograph signal from a sensor coupled to a body of a patient, and the method includes processing the photoplethysmograph signal so as to measure a heart rate of the patient.
  • processing the photoplethysmograph signal includes identifying at least one premature ventricular contraction (PVC) in a heart rhythm of the patient.
  • the method includes processing the photoplethysmograph signal so as to measure a vasomodulation in the body. Further additionally or alternatively, the method includes processing the photoplethysmograph signal so as to measure a modulation of respiration by the patient.
  • PVC premature ventricular contraction
  • receiving the signal includes receiving a photoplethysmograph signal from a sensor on a finger of the patient, and filtering the signal includes digitizing and filtering the signal so as to generate data using processing circuitry in a control unit that is fastened to a forearm of the patient, and storing the data in a memory in the control unit.
  • processing the filtered signal includes connecting the control unit to an external processor and uploading the data from the memory to the external processor for analysis, and storing the data includes receiving and recording the data in the control unit while the control unit is disconnected from the external processor.
  • receiving the signal includes receiving a photoplethysmograph signal from a sensor implanted in a body of the patient.
  • apparatus for diagnosis including: a sensor, which is configured to be coupled to a body of a patient during sleep and to output a signal associated with blood oxygen saturation in the body; and a processor, which is coupled to filter the signal so as to eliminate signal components at frequencies equal to and greater than a respiratory frequency of the patient, and to process the filtered signal to detect a pattern corresponding to multiple cycles of periodic breathing.
  • a computer software product including a computer-readable medium in which program instructions are stored, which instructions, when read by a computer, cause the computer to receive a signal associated with blood oxygen saturation in a body or a patient, and to filter the signal so as to eliminate signal components at frequencies equal to and greater than a respiratory frequency of the patient, and to process the filtered signal to detect a pattern corresponding to multiple cycles of periodic breathing.
  • Fig. 1 is a schematic, pictorial illustration of a system for sleep monitoring and diagnosis, in accordance with an embodiment of the present invention
  • Fig. 2A is a schematic, pictorial illustration of apparatus for patient monitoring, in accordance with an embodiment of the present invention
  • Fig. 2B is a block diagram that schematically shows functional elements of the apparatus of Fig. 2A, in accordance with an embodiment of the present invention
  • Figs. 3A and 3B are a flow chart that schematically illustrates a method for sleep monitoring and diagnosis, in accordance with an embodiment of the present invention
  • Fig. 4 is a schematic plot of photoplethysmograph and ECG signals, illustrating detection of a cardiac arrhythmia in accordance with an embodiment of the present invention.
  • Fig. 5 is a Kaplan-Meier plot that schematically shows survival of heart failure patients as a function of Brain Natriuretic Peptide (BNP) levels;
  • Fig. 6 is a Kaplan-Meier plot that schematically shows survival of heart failure patients as a function of BNP levels, with a threshold level determined by severity of Cheyne- Stokes breathing, in accordance with an embodiment of the present invention
  • Fig. 7 is a receiver operating characteristic (ROC) plot, which schematically shows the sensitivity and specificity of predicting heart failure prognosis in accordance with an embodiment of the present invention.
  • Fig. 8 is a Kaplan-Meier plot that schematically shows survival of heart failure patients as a function of the severity of symptoms classified by a method in accordance with an embodiment of the present invention.
  • Fig. 1 is a schematic, pictorial illustration of a system 20 for sleep monitoring and diagnosis, in accordance with an embodiment of the present invention.
  • system 20 is used to monitor a patient 22 in a home, clinic or hospital ward environment, although the principles of the present invention may similarly be applied in dedicated sleep laboratories.
  • System 20 receives and analyzes a photoplethysmograph signal from a suitable sensor, such as a pulse oximetry device 24.
  • Device 24 provides a photoplethysmograph signal indicative of blood flow and a signal indicative of the level of oxygen saturation in the patient's blood.
  • the photoplethysmograph signal is thus considered to be a signal that is associated with blood oxygen saturation.
  • system 20 may comprise sensors of other types (not shown), for collecting other physiological signals.
  • the system may receive an ECG signal, measured by skin electrodes, and a respiration signal measured by a respiration sensor.
  • the techniques of monitoring and analysis that are described herein may be combined with EEG, EOG, leg motion sensors, and other sleep and/or cardiac monitoring modalities that are known in the art.
  • console 28 may receive signals by telemetry from implantable cardiac devices, such as pacemakers and ICDs.
  • Console 28 may process and analyze the signals from pulse oximetry device 24 locally, using the methods described hereinbelow. hi the present embodiment, however, console 28 is coupled to communicate over a network 30, such as a telephone network or the Internet, with a diagnostic processor 32. This configuration permits sleep studies to be performed simultaneously in multiple different locations.
  • Processor 32 typically comprises a general-purpose computer processor (which may be embedded in a bedside or remote monitor) with suitable software for carrying out the functions described herein. This software may be downloaded to processor 32 in electronic form, or it may alternatively be provided on tangible media, such as optical, magnetic or non-volatile electronic memory.
  • Processor 32 analyzes the signals conveyed by console 28 in order, to analyze the physiological parameters, identify sleep stages, and extract prognostic information regarding patient 22, and to display the results of the analysis to an operator 34, such as a physician.
  • the embodiments described herein relate mainly to methods and apparatus for monitoring and diagnosis during sleep
  • the principles of the present invention may also be applied, mutatis mutandis, to patients who are awake.
  • these methods and apparatus may be used in monitoring patients who are reclining or otherwise at rest, even if they are not asleep.
  • FIG. 2 A is a pictorial illustration of the apparatus
  • Fig. 2B is a block diagram showing functional components of the apparatus.
  • Apparatus 21 is similar in functionality to elements of system 20, as shown in Fig. I 5 but apparatus 21 is particularly advantageous in that it can be worn comfortably by the patient during both sleep and waking hours and requires no wired connection to a console, except periodically (once a day, for example) for data upload and battery recharging.
  • pulse oximetry device 24 in apparatus 21 has the form of a ring, which fits comfortably over one of the fingers on a hand 23 of the patient (although other configurations of device 24 may alternatively be used in the apparatus).
  • Device 24 is connected by a wire to a control unit 25, which may conveniently be fastened around the patient's wrist. Alternatively, the control unit may be fastened elsewhere on the patient's forearm, at any suitable location between the hand and the elbow, or elsewhere on the patient's body.
  • the control unit may include a display 27, to present status information and/or readings of monitored parameters, such as heart rate, blood oxygen saturation and heart failure status.
  • a connector 29 on the control unit is configured to connect to a console or docking station. In the illustrated embodiment, connector 29 comprises a receptacle for a cable with a standard plug, such as a USB cable. Alternatively, the connector may mate directly with a matching connector on a dedicated docking station.
  • a sensor 31 (typically comprising two light source/light detector subassemblies, as described below) in device 24 is connected via wire to signal processing circuitry 33 in control unit 25.
  • the signal processing circuitry digitizes and filters the signals from sensor 31 and stores the results in a memory 35.
  • control unit 25 may transmit the results to a receiver using a suitable wireless communication protocol, such as Bluetooth® or ZigBee®).
  • circuitry 33 may also be configured to perform some of the additional processing functions that are shown in Figs. 3 A and 3B and described hereinbelow.
  • the signal processing circuitry and peripheral components are powered by an internal power source, such as a battery 38, so that apparatus 21 can perform its data collection functions without wired connection to a console or to lines power.
  • Apparatus 21 may also comprise an actigraph 39, which is typically contained in control unit 25.
  • the actigraph measures movement of the patient and typically comprises an accelerometer for this purpose.
  • the measurements of patient movement are recorded together with the data from sensor 31 in memory 35 and may be used in subsequent analysis to determine the patient's state of sleep or arousal.
  • control unit 25 After apparatus 21 has recorded patient data in memory 35 for a sufficient period of time, the user (who may be the patient himself or herself) connects control unit 25 to the docking station or other console via connector 29.
  • a controller 36 in the control unit is then able to communicate with the console or docking station via a suitable interface 37 (such as a USB interface in the example noted above).
  • the controller reads out the data that are stored in memory 35 to a processor, such as processor 32, which analyzes the data, as described hereinbelow.
  • interface 37 may comprise charging circuitry for recharging battery 38.
  • pulse oximetry device 24 may be configured either as shown in Fig. 1 or as shown in Figs. 2 A or 2B.
  • substantially any suitable sort of photoplethysmograph may be used in these embodiments, including a photoplethysmographic sensor that is implanted in the body of the patient.
  • An implantable oximeter that may be used for this purpose, for example, is described in U.S. Patent 6,122,536, whose disclosure is incorporated herein by reference.
  • the methods that are described hereinbelow may be used in conjunction with devices of other types that provide information on the breathing, oxygen saturation, and heart performances of the patient.
  • the methods described below are applied to the output of a non-contact respiratory monitor, such as the one described in U.S. Patent 6,011,477, whose disclosure is incorporated herein by reference.
  • DIAGNOSTIC METHOD such as the one described in U.S. Patent 6,011,477, whose disclosure is incorporated herein by reference.
  • Figs. 3A and 3B are a flow chart that schematically illustrates a method for sleep monitoring and diagnosis, in accordance with an embodiment of the present invention.
  • Pulse oximetry device 24 comprises two light source/light detector subassemblies 40 and 42. These subassemblies generate signals that are indicative of absorption and/or reflectance of light at two different wavelengths, typically one red and one infrared, as is known in the art. Each signal includes an AC component, which corresponds to the pulsatile change in the signal at the patient's heart rate, and a slow-changing DC component. Comparison of the AC components of the two signals gives a blood oxygen saturation signal 44.
  • at least some of the methods described below can use the signals from only a single source/detector subassembly, or signals provided by other types of photoplethysmographic sensors.
  • the saturation signal is low-pass filtered to give a very-low-frequency (VLF) saturation signal 46.
  • VLF very-low-frequency
  • This filtering removes signal components at frequencies that are greater than or equal to the patient's respiratory frequency, so that the signal remaining reflects trends over multiple respiratory cycles. In some embodiments, the filtering is even more pronounced, and eliminates frequency components outside the Cheyne-Stokes cycle frequency, for example, components below 1/180 Hz or above 1/40 Hz.
  • Processor 32 analyzes shape characteristics of the VLF saturation signal in order to detect episodes of Cheyne-Stokes breathing (CSB).
  • CSB Cheyne-Stokes breathing
  • this condition is characterized by a regular waxing and waning breathing pattern and occurs particularly among patients with heart failure and in patients who have experienced a stroke.
  • CSB is present during sleep, and in more severe cases may also be observed during wakefulness.
  • Cheyne-Strokes breathing syndrome (CSBS) is characterized by the following criteria: 1. Presence of congestive heart failure or cerebral neurological disease.
  • Respiratory monitoring demonstrates: i. At least three consecutive cycles of a cyclical crescendo and decrescendo change in breathing amplitude. Cycle length is most commonly in the range of 60 seconds, although the length may vary. ii. One or both of the following:
  • N Five or more central sleep apneas or hypopneas per hour of sleep.
  • H The cyclic crescendo and decrescendo change in breathing amplitude has duration of at least 10 consecutive minutes.
  • the decrescendo phase is associated with decreased respiratory effort and rate (hypopnea/apnea); decrease in oxygen saturation; decrease in heart rate; and vasodilation, manifested in decreased blood pressure.
  • the crescendo phase has the opposite effects: increase in respiratory effort and rate, i.e. hyperpnea; increase in heart rate; and vasoconstriction, leading to increased blood pressure.
  • hyperpnea is accompanied by an arousal, which is manifested as a motion artifact in the photoplethysmograph signal.
  • the changes in heart rate and vasomotion depend on the severity of the heart failure, as discussed below.
  • processor 32 uses the shape characteristics of the VLF saturation signal in measuring time characteristics 48 of the patient's Cheyne-Stokes episodes. Specifically, the processor detects desaturation episodes extending over multiple consecutive Cheyne-Stokes breathing cycles in order to identify the presence of CSBS. ha order to detect and measure the duration of multi-cycle Cheyne-Stokes episodes, processor 32 typically locates the local maxima and local minima of the VLF saturation signal.
  • the processor may also compute the difference between the maximal and minimal saturation values (in the unsmoothed saturation signal 44), as well as the corresponding wavelengths.
  • the processor extracts time sequences of cyclic breathing with similar desaturation values and similar wavelengths, falling in the range that is characteristic of - Cheyne-Stokes cycles. (Typically only a certain percentage, such as 80%, of the desaturation and wavelength values are required to be close to the median values of the sequence, in order to avoid losing sequences due to intervening outliers. For example, a 50% deviation from the median value of
  • 80% of the wavelength and desaturation values may be accepted for a sequence that is at least of a certain minimum duration, such as 5 min.)
  • the processor chooses the longest segments that meet the above similarity criteria. Alternatively, a hysteresis procedure may be used to ensure robustness against outliers.
  • the total Cheyne-Stokes time is then computed as the total duration of all the segments that are classified as Cheyne-Stokes breathing events.
  • the inventors conducted a clinical trial, which included 91 full-night ambulatory polysomnography tests for patients with advanced heart failure. Cheyne-Stokes episodes were marked manually by an experienced scorer, and these manual results were compared to the results of the automatic process described above. The correlation between manual automatic scoring was 83%, which is as good as the typical correlation between different human scorers.
  • processor 32 evaluates the slope of the saturation signal (or of the DC component of the pulse oximeter signal) for each desaturation event.
  • the slope of the exit from the cycle is moderate, i.e., it is similar to the typical (or specific) entry slope. Therefore, to identify a time sequence of cyclic breathing as Cheyne-Stokes, processor 32 requires that the sequence comprise mainly (typically at least 80%) events of moderate slope.
  • “Envelopes” may also be derived by other mathematical operations known in the art, such as application of Hubert transforms.
  • processor 32 may validate the prognostic value of the Cheyne-Stokes marker by considering only events with mild exit slope from desaturation events.
  • the inventors found that computing the slope of the saturation curve by fitting a line (by the least-square method) to the curve over a nine-second epoch, and requiring that the slope of the line be less then 0.7 percent/second is a good implementation of this mild desaturation condition.
  • Processor 32 associates each segment with its segment duration and with its median desaturation value.
  • the features of the Cheyne-Stokes segments are prognostic of patient outcome in cases of heart failure (and other illnesses). Long wavelength, in particular, is associated with bad prognosis.
  • processor 32 typically detects signal components that have a period greater than a minimum period of at least 30 sec. In the marker validation experiments that are described herein, the inventors required the median cycle length to be above 55 seconds and the median desaturation value to be no less the 2% in order to classify a periodic breathing pattern as Cheyne-Stokes breathing.
  • time segments with steep exit saturation slope typically correspond to obstructive apnea/hypopnea events.
  • Other features of obstructive apnea/hypopnea time segments include short wavelength, large vasomotion, and large heart rate modulations. These phenomena are generally associated with good prognosis, since they reflect the patient's ability to manifest enhanced sympathetic activity.
  • processor 32 may also process an AC absorption or reflectance signal 52 that is output by device 24 in order to compute a heart rate 54, as is known in the art. Furthermore, the AC signal may be analyzed to detect a beat morphology 56. The processor identifies certain aberrations in this morphology as arrhythmias, such as premature ventricular contractions (PVCs) 58. It keeps a record of the occurrences of such arrhythmias, in a manner similar to a Holter monitor, but without requiring the use of ECG leads. The total number of abnormal heart beats and (specifically PVCs) that are accumulated in such a record, particularly during sleep, is indicative of bad prognosis. As the inventors have found that premature beats during sleep have the greatest prognostic value for advanced heart failure patients, the processor may be configured to count the number of premature beats only during sleep or during episodes of Cheyne-Stokes breathing.
  • PVCs premature ventricular contractions
  • Fig. 4 is a schematic plot of an AC photoplethysmograph signal 60, alongside a corresponding ECG signal 62, illustrating a method for detection of PVCs in accordance with an embodiment of the present invention.
  • Signal 60 can be seen to comprise a series of regular waveforms, which are indicative of arterial blood flow.
  • a PVC is manifested as an aberrant waveform 64 in signal 60 s and likewise by an abnormal waveform 66 in signal- 62.
  • Processor 32 analyzes the shape, amplitude and timing of waveform 64 in the plethysmograph signal in order to determine that the aberrant wave represents PVC, even without the use of any sort of ECG monitoring.
  • arrhythmias are identified in photoplethysmograph signal 60 based on the following features:
  • Local maxima and minima are extracted from the signal in segments of the signal whose length is less than the typical RR interval (i.e., the typical time difference between successive heart beats). For example, 0.3 seconds is an appropriate segment length for this purpose.
  • the width of each beat is defined, for example by measuring the time difference between successive locations of photoplethysmograph signal values whose energy is equal to the average (possibly a weighted average) of the local maximum and minimum.
  • Beats with short width typically correspond to PVCs, as shown in Fig. 4.
  • the number of such beats is a measure of the severity of arrhythmia.
  • An additional criterion for detecting an arrhythmia is that the time span of two beats, one of which has a short width, is roughly equal to the time span of two normal beats.
  • Fig. 4 and the above description relate specifically to PVCs, the principles of this embodiment may likewise be applied in detecting other types of premature heart beats, as well as various other types of heartbeat irregularities. Such irregularities are associated with reduced stroke volume, which in turn affect the amplitude, width and other features of the photoplethysmograph waveform.
  • FIG. 3A Other types of aberrant waveforms in photoplethysmograph signal 60 may correspond to motion artifacts 80 (listed in Fig. 3A, but not shown in Fig. 4).
  • Motion is characterized by local maxima well above normal beat range (for example, at least twice the normal value).
  • the prevalence of motion artifacts can be used in detecting movement, which indicate whether the patient is in a sleep or waking state 82.
  • a motion sensor may be used to detect arousals.
  • processor 32 may additionally extract other cardiorespiratory parameters from signal 52, either directly or indirectly.
  • the processor may apply very-low-frequency filtering to heart rate 54 in order to detect heart rate modulations 70.
  • the envelope of signal 52 may be processed in order to detect characteristics of vasomodulation 72, i.e., arterial dilation and constriction.
  • processor 32 may compute a respiration energy and/or rate characteristic 74 based on high-frequency components of signal 52.
  • Respiratory sinus arrhythmia is a natural cycle of arrhythmia that occurs in healthy people through the influence of breathing on the flow of sympathetic and vagus impulses to the sinoatrial node in the heart. This effect may be used to calculate respiration from heart rate.
  • Well-treated heart failure patients are frequently under the control of cardiac pacemakers and often take beta-blockers and ACE inhibitors that suppress this phenomenon.
  • High-frequency (10-30 cycles/min, i.e., 0.17-0.5 Hz) filtering of the photoplethysmograph signal enables the processor to determine respiration energy and/or rate characteristics in these cases, as well.
  • Very-low-frequency components of characteristic 74 are indicative of a respiration modulation 76.
  • Processor 32 combines the various cardiac, respiratory and vasomodulation parameters described above in order to provide a general picture of cardiorespiratory effects 78, all on the basis of the photoplethysmograph signals.
  • detrending Similar procedures to those described above can be applied to the detrended AC photoplethysmograph signal.
  • One way to perform detrending is to replace the photoplethysmograph signal with its amplitude feature (maximum minus minimum signal).
  • Other methods include subtracting a polynomial that approximates the signal, or using local maxima or local minima features.
  • the processor applies very-low-frequency filtering followed by outlier rejection, and then computes the median vasomotion of each sequence.
  • the processor may perform similar analyses on heart rate and respiratory signals from other sources. Arousals can estimated from motion artifacts as described above or from other data if available (such as EEG alpha and beta frequencies, or scorer marking, or a motion sensor). Information regarding sleep/wake state 82 is combined with Cheyne-Stokes time 48 to determine specific, cumulative Cheyne-Stokes time 84 during sleep. The total Cheyne-Stokes time and percentage of Cheyne-Stokes time during sleep have prognostic value: A large percentage of Cheyne-Stokes time is associated with mortality and high levels of brain natriuretic peptide (BNP) 5 which are associated with severity of heart failure.
  • BNP brain natriuretic peptide
  • information about sleep time can be used to ensure that low Cheyne-Stokes duration is not associated with little or no sleep.
  • the inventors have determined the prognostic value of total Cheyne-Stokes time only in patients who slept for at least a certain minimal duration, such as two hours.)
  • the prognostic value of Cheyne-Stokes information derived in the above manner is illustrated in Figs. 5-8 below.
  • Cheyne-Stokes time 84 is combined with the general picture of cardiorespiratory effects 78 in order to provide some or all of the following combined information 86 for each Cheyne-Stokes sequence during sleep:
  • arousal index number of arousals
  • the above-mentioned median functions may be replaced by similar functions based on average values or average of values in the middle tertile, inter-quartile range, or any other appropriate segment.
  • Each of the above parameters can also be computed separately for REM sleep and NREM sleep.
  • the following criteria may be applied to the various processed outputs of oximetry device 24 in order to derive information 86 and measure the manifestations of Cheyne-Stokes breathing:
  • the saturation signal is filtered in the Cheyne-Stokes frequency range, typically 1/180 - 1/40 Hz. 2.
  • a time segment is identified as a Cheyne-Stokes event (and the durations of such time segments are summed) if the segment contains a sequence of at least three cycles of desaturation for which: i. Median desaturation (compared to the previous saturation level) is at least 2%. Alternatively, another representative saturation level, such as the mean or minimum, may be used, ii. Mean cycle length is long (55-180 sec). (Short cycle length is not associated with bad prognosis.) iii. Cycle length fluctuation within each sequence may optionally be limited (to less then 10% fluctuation, for example). iv.
  • Moderate vasomotion based on at least one of the following: tt.
  • Median of maximal desaturation slope in each cycle is less then a maximum slope limit, such as 0.7 percent/sec, (by least squares fit of a line to the desaturation curve); Alternatively, a measure of mean slope may be used.
  • respiration characteristic 74 may be required to reach a minimum indicating zero respiratory effort during the cycle. This minimum may be identified based on the VLF components of characteristic 74 in respiration modulation 76.
  • Outlier rejection procedures may be applied to the saturation and respiration values before classifying time segments. For example: i. As noted above, a certain fraction (typically up to 20%) of the desaturation and wavelength values may be far from the median values of the sequence, and extreme desaturations (for example, >50%) may be rejected as faulty readings, ii.
  • the mean cycle length can be calculated after discarding values that are far from the mean (for example, values in the top and bottom deciles.) iii. Consistency may be enforced by permitting the relation between cycle length and desaturation to vary linearly within given bounds. 5.
  • self-similarity measures can be used in identifying sequences of Cheyne-Stokes cycles. For example, a distinct peak in the 1/180 - 1/40 Hz range of the Fourier transform of the sequence of periodic breathing cycles or high autocorrelation of the cycles is an indicator of such self-similarity.
  • Cheyne-Stokes respiration segments can be found by applying the above criteria to the respiration signal (excluding the computations that relate to saturation values).
  • sleep/wake state 82 may be combined with analysis of cardiorespiratory and Cheyne-Stokes effects in order to perform automatic sleep staging 88.
  • All of the factors that are used in determining the sleep stage may be derived solely from the signals generated by oximetry device 24. Alternatively, other signals may be incorporated into the sleep staging calculation.
  • Sleep states are classified by processor 32 -as light sleep, deep slow- wave sleep (SWS) 90 and REM 92.
  • SWS deep slow- wave sleep
  • REM sleep the patient is partially paralyzed, so that there is no motion.
  • the Cheyne-Stokes wavelength tends to be longer and the desaturation deeper in REM sleep that in light sleep.
  • Others factors characterizing deep sleep include regularity of respiratory cycle length and low vasomotion.
  • Processor 32 may use the distribution of sleep stages and of apnea events during sleep in computing a sleep quality index 94.
  • apnea-free (or nearly apnea-free) segments in non-SWS sleep are indicative of good prognosis for heart failure patients.
  • low percentages of REM or SWS indicate a- poor prognosis.
  • Cheyne-Stokes breathing and attendant heart failure prognosis may be used conveniently in performing frequent checks on patient status, both at home and in the hospital. Additionally or alternatively, occasional checks of this sort may be used for risk stratification and screening. As explained above, these methods may be implemented using measurements made solely by pulse oximetry device 24, or alternatively in conjunction with other sensors, as in a multi-monitor polysomnography system, or in an implantable device, or using other types of respiratory sensors.
  • the inventors compared Cheyne-Stokes time with heart failure status in 91 tests of advanced heart failure patients. Results of this study are presented below.
  • the cumulative duration of Cheyne-Stokes breathing during a night's sleep was measured, wherein Cheyne-Stokes cycles were identified as described above (including the requirements of mild slope - up to 0.7 percent/sec, median desaturation of at least 2%, and median cycle length of 55 to 180 sec.)
  • the status of the patients was determined by six-month survival and BNP levels, which are generally considered the best marker for heart failure status. For this purpose, a blood sample was drawn from each patient and tested for NT-proBNP on the night of the sleep study.
  • NT-proBNP Serum N-terminal prohormone Brain Natriuretic Peptide
  • Elecsys® proBNP electro-chemiluminescence immunoassay run on the Elecsys 1010 benchtop analyzer (Roche Diagnostics, Indianapolis, Indiana).
  • Fig. 5 is a Kaplan-Meier plot of patient survival according to the standard BNP kit values. According to accepted diagnostic standards, a state of decompensated heart failure is associated with a serum NT-proBNP level above 450, 900, or 1,800 pg/mL for patients whose age is less than 50, 50-75, or above 75, respectively.
  • An upper trace 70 shows the rate of survival over time for the patients with low BNP (below the decompensation threshold), while an upper trace 72 shows the rate for patients with high BNP.
  • Fig. 6 is a Kaplan-Meier plot of patient survival according to the automated Cheyne-Stokes marker described above, in accordance with an embodiment of- the present invention.
  • an upper trace 74 shows the survival rate of the patients who had low cumulative duration of Cheyne-Stokes breathing episodes
  • a lower trace 76 shows the survival rate for patients with high cumulative Cheyne-Stokes duration.
  • the inventors have found that typically, a cumulative duration of Cheyne-Stokes breathing episodes in excess of 45 minutes during a night's sleep is indicative of poor prognosis.
  • the Cheyne-Stokes cutoff 48 minutes was selected to best predict BNP cutoff according to the standard guidelines described above.
  • Fig. 7 is a receiver operating characteristic (ROC) plot, which schematically compares the sensitivity and specificity of predicting heart failure prognosis using BNP and duration of Cheyne-Stokes breathing episodes, as measured in accordance with an embodiment of the present invention.
  • An upper trace 78 is the ROC curve for Cheyne-Stokes duration, while a lower trace 80 is the ROC curve for the BNP marker.
  • both Cheyne-Stokes duration and BNP were tested against six-month mortality of the patients in the study.
  • the plot shows that the Cheyne-Stokes marker gives greater sensitivity and specificity.
  • Fig. 8 is a Kaplan-Meier plot of six-month survival of the heart failure patients as a function of the severity of symptoms classified by the methods described above, in accordance with another embodiment of the present invention.
  • patients were classified into two groups: one group with severe Cheyne-Stokes breathing coupled with cardiac arrhythmia, and the other with breathing and heart rhythm that showed mild or no symptoms of these kinds.
  • patients who exhibited at least 200 premature beats in the course of the night's sleep were classified as suffering from cardiac arrhythmia.
  • An upper trace 82 in the figure shows the survival rate for the group with mild or no symptoms, while a lower trace 84 shows the survival rate for patients in the severe/arrhythmic group.
  • FIGs. 5-8 show that photoplethysmographic monitoring during sleep may be used effectively for the prognosis of heart failure patients.
  • this sort of monitoring is simple to carry out in the patient's home or hospital bed and may be performed at regular intervals, at low cost and minimal discomfort to the patient. It provides physicians with an accurate prognostic indicator, which they can use in choosing the optimal treatment, such as determining whether a patient requires hospitalization, and adjusting treatment parameters (such as drug titration) based on changes in the patient's condition.
  • the physician may measure and quantify the patient's symptoms (Cheyne-Stokes duration and possibly arrhythmias) prior to initiating or making a change in treatment, and may repeat the measurement thereafter in order to assess the effectiveness of the treatment and possibly readjust treatment parameters.
  • the physician may fix a specific critical Cheyne-Stokes duration for individual patients, and then set a monitoring system to alarm whenever a specific duration is exceeded.
  • respiration signals captured by any other suitable type of sensor may be based, for example, on electrical measurements of thoracic and abdominal movement, using skin electrodes to make a plethysmographic measurement of the patient's respiratory effort, or a belt to sense changes in the body perimeter. Additionally or alternatively, air flow measurement, based on a pressure cannula, thermistor, or CO2 sensor, may be used for respiration sensing. In other embodiments of the present invention, a capnograph may be used in detecting sleep apneas, either in conjunction with or separately from the pulse oximeter used in the techniques described above.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Optics & Photonics (AREA)
  • Anesthesiology (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)

Abstract

L'invention porte sur un procédé de diagnostic qui consiste à recevoir un signal associé à la saturation en oxygène du sang d'un patient (22) au cours du sommeil. On filtre le signal afin d'éliminer les composantes du signal à des fréquences supérieures ou égales à la fréquence respiratoire du patient. On traite le signal filtré afin de détecter un profil correspondant à de multiples cycles de respiration périodique.
EP07805552A 2006-09-07 2007-09-04 Détection de l'insuffisance cardiaque au moyen d'un photopléthysmographe Withdrawn EP2091428A4 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US84310706P 2006-09-07 2006-09-07
US11/750,222 US7803118B2 (en) 2004-11-22 2007-05-17 Detection of heart failure using a photoplethysmograph
US11/750,221 US7674230B2 (en) 2004-11-22 2007-05-17 Sleep monitoring using a photoplethysmograph
US11/750,250 US7803119B2 (en) 2004-11-22 2007-05-17 Respiration-based prognosis of heart disease
US11/750,173 US7794406B2 (en) 2004-11-22 2007-05-17 Detection of cardiac arrhythmias using a photoplethysmograph
PCT/IL2007/001092 WO2008029399A2 (fr) 2006-09-07 2007-09-04 Détection de l'insuffisance cardiaque au moyen d'un photopléthysmographe

Publications (2)

Publication Number Publication Date
EP2091428A2 true EP2091428A2 (fr) 2009-08-26
EP2091428A4 EP2091428A4 (fr) 2012-05-30

Family

ID=40886597

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07805552A Withdrawn EP2091428A4 (fr) 2006-09-07 2007-09-04 Détection de l'insuffisance cardiaque au moyen d'un photopléthysmographe

Country Status (2)

Country Link
EP (1) EP2091428A4 (fr)
WO (1) WO2008029399A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009118737A2 (fr) * 2008-03-27 2009-10-01 Widemed Ltd. Diagnostic d'une respiration périodique
JP2013533021A (ja) * 2010-06-23 2013-08-22 オリディオン メディカル １９８７ リミテッド 睡眠障害分析のための方法およびシステム
EP2687154B8 (fr) * 2012-07-20 2019-09-11 CSEM Centre Suisse d'Electronique et de Microtechnique SA - Recherche et Développement Dispositif portable et procédé pour déterminer un paramètre de sommeil d'un utilisateur
GB2505890A (en) * 2012-09-12 2014-03-19 To Health Ltd Screening to determine a cardiac arrhythmia risk parameter using photoplethysmograph measurements
KR102270209B1 (ko) * 2014-10-28 2021-06-29 삼성전자주식회사 신체 착용형 전자 장치
US10932727B2 (en) 2015-09-25 2021-03-02 Sanmina Corporation System and method for health monitoring including a user device and biosensor
EP3399913A4 (fr) * 2016-01-10 2019-12-18 Sanmina Corporation Système et procédé de surveillance médicale comprenant un dispositif utilisateur et un biocapteur
US20190053754A1 (en) * 2017-08-18 2019-02-21 Fitbit, Inc. Automated detection of breathing disturbances
CN111163695B (zh) * 2017-09-29 2023-09-12 京瓷株式会社 睡眠判定系统、按摩系统、控制方法及电子设备
BR112020013185A2 (pt) * 2017-12-28 2020-12-01 Profusa, Inc. sistema e método para analisar dados de sensor bioquímico
CN109464128A (zh) * 2019-01-09 2019-03-15 浙江强脑科技有限公司 睡眠质量检测方法、装置及计算机可读存储介质
CN110623652B (zh) * 2019-09-17 2021-10-19 荣耀终端有限公司 数据显示方法及电子设备

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001076459A2 (fr) * 2000-04-10 2001-10-18 The Research Foundation Of State University Of New York Procede permettant de detecter la respiration de cheyne-stokes chez des patients souffrant d'insuffisance cardiaque congestive
WO2002087433A1 (fr) * 2001-04-30 2002-11-07 Medtronic, Inc. Methode et appareil de detection et de traitement d'evenements respiratoires pendant le sommeil
WO2006066337A1 (fr) * 2004-12-23 2006-06-29 Resmed Limited Procede de detection et de differentiation des modes respiratoires a partir de signaux respiratoires

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6223064B1 (en) * 1992-08-19 2001-04-24 Lawrence A. Lynn Microprocessor system for the simplified diagnosis of sleep apnea
US6839581B1 (en) * 2000-04-10 2005-01-04 The Research Foundation Of State University Of New York Method for detecting Cheyne-Stokes respiration in patients with congestive heart failure
US6589188B1 (en) * 2000-05-05 2003-07-08 Pacesetter, Inc. Method for monitoring heart failure via respiratory patterns

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001076459A2 (fr) * 2000-04-10 2001-10-18 The Research Foundation Of State University Of New York Procede permettant de detecter la respiration de cheyne-stokes chez des patients souffrant d'insuffisance cardiaque congestive
WO2002087433A1 (fr) * 2001-04-30 2002-11-07 Medtronic, Inc. Methode et appareil de detection et de traitement d'evenements respiratoires pendant le sommeil
WO2006066337A1 (fr) * 2004-12-23 2006-06-29 Resmed Limited Procede de detection et de differentiation des modes respiratoires a partir de signaux respiratoires

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2008029399A2 *

Also Published As

Publication number Publication date
WO2008029399A2 (fr) 2008-03-13
WO2008029399A3 (fr) 2009-05-07
EP2091428A4 (fr) 2012-05-30

Similar Documents

Publication Publication Date Title
US7803118B2 (en) Detection of heart failure using a photoplethysmograph
EP2091428A2 (fr) Détection de l'insuffisance cardiaque au moyen d'un photopléthysmographe
EP1711104B1 (fr) Procede et dispositif permettant de surveiller, de detecter et de classifier des troubles respiratoires du sommeil a partir d'un electrocardiogramme
US20110054279A1 (en) Diagnosis of periodic breathing
JP6333170B2 (ja) 人の睡眠および睡眠段階を決定するシステムおよび装置
US8992434B2 (en) Prediction and monitoring of clinical episodes
US7314451B2 (en) Techniques for prediction and monitoring of clinical episodes
CN109310347B (zh) 生理和病理生理睡眠条件的非侵入性检测方法和装置
CN115209801A (zh) 睡眠呼吸暂停检测系统和方法
CN111466906A (zh) 穿戴式睡眠监测仪及监测方法
CN111867450A (zh) 睡眠呼吸暂停检测系统和方法
Leier et al. Respiration signal extraction from photoplethysmogram using pulse wave amplitude variation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090407

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120426

RIC1 Information provided on ipc code assigned before grant

Ipc: A61B 5/1455 20060101ALI20120420BHEP

Ipc: A61B 5/08 20060101AFI20120420BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140401